Ironwood Pharmaceuticals INC 8-K filings

Ironwood Pharmaceuticals reported strong second quarter 2026 results, exceeding expectations and leading to an increase in full-year financial guidance for LINZESS net sales, total revenue, and adjusted EBITDA.

Ironwood Pharmaceuticals' stockholders approved an amendment to its 2019 Equity Incentive Plan, increasing the share pool by 10 million shares.

Ironwood Pharmaceuticals announced the resignation of its CFO, Gregory Martini, effective May 15, 2026, with Ronald Silver appointed as interim CFO.

Ironwood Pharmaceuticals announced robust first quarter 2026 financial results, driven by a significant 97% year-over-year increase in LINZESS U.S. net sales, while maintaining full-year financial guidance.

Ironwood Pharmaceuticals reported strong fourth quarter and full-year 2025 results, surpassing financial guidance and reiterating an optimistic 2026 outlook driven by LINZESS and apraglutide.

Ironwood Pharmaceuticals announced robust financial guidance for full-year 2026, projecting significant increases in LINZESS U.S. net sales, total revenue, and adjusted EBITDA, while maintaining its 2025 guidance.

Ironwood Pharmaceuticals' subsidiary, VectivBio, has settled a patent dispute with Ferring International Center S.A. and amended their exclusive license agreement, involving a $12.5 million payment and revised royalty structure.

The U.S. Department of Health and Human Services has set the Maximum Fair Price for Ironwood Pharmaceuticals' LINZESS at $136 per 30-day supply, effective January 1, 2027, aligning with the company's expectations.

Ironwood Pharmaceuticals reported robust third-quarter 2025 results, driven by strong LINZESS sales and a significant FDA approval, leading to raised full-year financial guidance.

Andrew Dreyfus has resigned from Ironwood Pharmaceuticals' Board of Directors, effective November 1, 2025, to lead the NIHCM Foundation.

Ironwood Pharmaceuticals, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving a previously disclosed listing issue.

Ironwood Pharmaceuticals reported a return to GAAP net income in Q2 2025, driven by robust LINZESS sales growth and improved margins, while maintaining full-year financial guidance and progressing strategic alternatives.

Ironwood Pharmaceuticals, Inc. has dismissed Ernst & Young LLP as its independent auditor and appointed KPMG LLP, following EY's adverse opinion on the company's internal controls over financial reporting for 2024 due to material weaknesses.

Ironwood Pharmaceuticals, Inc. announced that its stockholders re-elected all nine director nominees, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as its independent auditor at the 2025 Annual Meeting.

Ironwood Pharmaceuticals, Inc. has received a deficiency letter from Nasdaq for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Ironwood Pharmaceuticals announced its Q1 2025 results, highlighting strong LINZESS prescription demand but a decrease in total revenue, while raising its adjusted EBITDA guidance for the year.

Ironwood Pharmaceuticals reiterates its full-year 2025 LINZESS U.S. net sales guidance of $800-$850 million and total Ironwood revenue of $260-$290 million, while raising its adjusted EBITDA guidance to greater than $105 million.

Ironwood Pharmaceuticals announces that a confirmatory Phase 3 trial is needed for apraglutide approval and the company is exploring strategic alternatives.

Ironwood Pharmaceuticals received a notification from Nasdaq regarding non-compliance with listing rules due to a delay in filing its 2024 Annual Report on Form 10-K.

Ironwood Pharmaceuticals announces Q4 and full year 2024 results, highlighting progress with apraglutide and LINZESS prescription demand growth, while also reporting a decrease in total revenue and U.S. LINZESS net sales.

Ironwood Pharmaceuticals announces a 50% workforce reduction and the appointment of Gregory Martini as Senior Vice President, Chief Financial Officer.

Ironwood Pharmaceuticals' CFO, Sravan K. Emany, has resigned, effective December 18, 2024, with CEO Thomas McCourt stepping in as interim CFO.

Ironwood Pharmaceuticals' Senior Vice President and Chief Business Officer, Andrew Davis, has resigned, effective November 22, 2024.

Ironwood Pharmaceuticals reported a 13% year-over-year increase in LINZESS prescription demand for Q3 2024, but experienced a decline in overall revenue and profitability compared to the same period last year.

Ironwood Pharmaceuticals has amended its revolving credit agreement, increasing the facility by $50 million to $550 million and extending the maturity date to December 31, 2028.

Ironwood Pharmaceuticals reported an 11% increase in LINZESS prescription demand year-over-year for Q2 2024, but revised its full-year financial guidance due to pricing pressures.

Ironwood Pharmaceuticals held its 2024 Annual Meeting of Stockholders, where nine director nominees were elected, executive compensation was approved on an advisory basis, and Ernst & Young LLP was ratified as the company's independent auditor for 2024.

Ironwood Pharmaceuticals has appointed Sravan K. Emany as Chief Operating Officer and Chief Financial Officer and fully repaid its $200 million convertible notes.

Ironwood Pharmaceuticals reported a decrease in revenue due to a LINZESS gross-to-net adjustment, but highlighted positive clinical trial results for apraglutide and strong LINZESS prescription demand.

Ironwood Pharmaceuticals achieved its 2023 financial guidance, driven by a 7% increase in U.S. LINZESS net sales to $1.1 billion and a 10% growth in prescription demand.